Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.0K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.6K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.6K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

3.3K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.3K
Embryonic Stem Cells00:58

Embryonic Stem Cells

32.4K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.4K
Cell Lines01:16

Cell Lines

10.3K
A cell line is a population of cells grown in vitro that can be subcultured over several generations. Normal cells cease to divide after a certain number of cell divisions, a process known as replicative senescence. This number, called the Hayflick limit, was conceptualized by Leonard Hayflick in 1961 when he observed that fetal cells grown in culture could only divide 40-60 times. This limit is due to the shortening of the telomeres during each round of cell division, preventing cell division...
10.3K
Adult Stem Cells01:33

Adult Stem Cells

33.8K
Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously...
33.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pluripotent stem cell lines available for use in clinical applications: A comprehensive overview.

Stem cell reports·2026
Same author

Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies.

Stem cell reports·2026
Same author

Pluripotent stem cell lines available for use in clinical applications: A comprehensive overview.

Stem cell reports·2025
Same author

Xenogeneic-free defined conditions for derivation and expansion of human embryonic stem cells with mesenchymal stem cells.

Regenerative therapy·2019
Same author

The Future State of Newborn Stem Cell Banking.

Journal of clinical medicine·2019
Same author

INDEX-db: The Indian Exome Reference Database (Phase I).

Journal of computational biology : a journal of computational molecular cell biology·2019

Related Experiment Video

Updated: Jan 31, 2026

Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation
09:51

Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation

Published on: February 2, 2016

14.2K

Concise review: making and using clinically compliant pluripotent stem cell lines.

Melissa K Carpenter1, Mahendra S Rao2

  • 1Carpenter Group Consulting Inc., Black Diamond, Washington, USA; NxCell Inc., Novato, California, USA; Q Therapeutics Inc., Salt Lake City, Utah, USA.

Stem Cells Translational Medicine
|February 28, 2015
PubMed
Summary
This summary is machine-generated.

Advancing pluripotent stem cell (PSC) therapies requires overcoming manufacturing and regulatory hurdles. A proposed NIH model and regulatory adjustments can accelerate PSC-based cell therapy implementation.

Keywords:
Current Good Manufacturing PracticePluripotent stem cellStem cellsTherapy

More Related Videos

Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions
10:48

Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions

Published on: November 26, 2014

8.3K
Transfecting and Nucleofecting Human Induced Pluripotent Stem Cells
10:24

Transfecting and Nucleofecting Human Induced Pluripotent Stem Cells

Published on: October 5, 2011

22.0K

Related Experiment Videos

Last Updated: Jan 31, 2026

Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation
09:51

Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation

Published on: February 2, 2016

14.2K
Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions
10:48

Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions

Published on: November 26, 2014

8.3K
Transfecting and Nucleofecting Human Induced Pluripotent Stem Cells
10:24

Transfecting and Nucleofecting Human Induced Pluripotent Stem Cells

Published on: October 5, 2011

22.0K

Area of Science:

  • Regenerative Medicine
  • Cell Therapy
  • Stem Cell Biology

Background:

  • Pluripotent stem cells (PSCs) are advancing rapidly, with new methods for derivation and generation.
  • Companies are preparing for clinical trials using human PSC derivatives under Good Manufacturing Practice (GMP).

Purpose of the Study:

  • To review the challenges in manufacturing, storing, and distributing PSC-derived biological products.
  • To discuss regulatory and cost barriers for PSC-based cell therapies.
  • To present a model for cost reduction and innovation in PSC research.

Main Methods:

  • Review of current advances in PSC derivation and manufacturing.
  • Analysis of challenges in tissue sourcing, production, storage, and distribution.
  • Description of a proposed National Institutes of Health (NIH) model for cost reduction and flexibility.

Main Results:

  • Significant technological advances are driving the field of PSCs.
  • Manufacturing, regulatory, and cost challenges impede clinical translation.
  • A proposed NIH model offers a framework for cost reduction and innovation.

Conclusions:

  • Addressing manufacturing and regulatory challenges is crucial for PSC-based cell therapy.
  • The NIH model, with regulatory adjustments, can accelerate the implementation of PSC therapies.
  • Optimizing production and regulatory pathways is key to realizing the potential of PSCs.